IMPORTANT INFORMATION ABOUT TRIKAFTA™ FOR UW HEALTH CF PATIENTS AND FAMILIES
Trikafta™ (elexacaftor/ivacaftor/tezacaftor) is a new treatment available for the most common form of cystic fibrosis. The FDA announced its approval on October 21, 2019.
Who is eligible for Trikafta?
Trikafta is approved for CF patients ages 12 or older and who have at least one copy of the F508del mutation. Eligible patients will require prior authorization before starting treatment, and have had blood testing for ALT, AST and bilirubin within the past six months. A baseline eye exam is also required to be on file prior to starting Trikafta.
What else should we know?
There is a possibility that insurance companies, Medical Assistance or pharmacy benefit managers (such as Navitus) could slow down the approval process.
Is Trikafta available right now?
Trikafta will not be in the specialty pharmacies until the middle to the end of the week beginning October 28, 2019. Please be aware that many of your care team members will be attending the North American Cystic Fibrosis Conference October 30 through November 2.
Your CF Care team at American Family Children’s Hospital is creating a list of patients to contact about starting Trikafta. We will first reach out to patients with the poorest lung function and then contact other CF patients in decreasing order of the severity of their disease.
We understand the urgency of treatment for all eligible CF patients. Our goal is to place all eligible patients on Trikafta over the coming weeks and months. We share your excitement about this breakthrough and appreciate your patience in this process.